BRAF and colorectal cancer: Currently, another prospective post-marketing surveillance study is ongoing in Japan as a pharmacovigilance activity of the triplet and double regimens for BRAF V600E-mutated colorectal cancer patients to assess the safety and efficacy of each regimen.